Overview
For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing allo-HSCT, the conditioning regimen will be 5-day Fludarabine, 2-day Busulifan and 2-day melphalan
Description
For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing allo-HSCT, the conditioning regimen will be Fludarabine (30mg/m2, d-7 to d-3) + Busulifan 3.2mg/kg (d-7 to d-6) + melphalan 70mg/m2 (d-4 and d-3). The GVHD prophylaxis will be PT-CY (Cyclophosphamide 50mg/kg d+3 and d+4) + low-dose ATG (2.5mg/kg) on d+15.
Eligibility
Inclusion Criteria:
- acute myeloid leukemia (CR1 or CR2) or myelodysplasia syndrome
- patients with HLA matched sibling, unrelated or Haplo-identical donor
Exclusion Criteria:
- patients with active infection
- patients with abnormal liver function damage: ALT/AST above 2X normal range
- patients with abnormal renal function damage Scr>160mol/L;
- patients with insufficient pulmonary function (FEV1FVCDLCO<50%and heart failure or with EF <50%)
- patients with mental instability or unwilling to give inform consent